Navigation Links
Aderans Research Treats One-Hundredth Subject in Clinical Study
Date:2/28/2010

Aderans Research Institute Inc. (ARI) recently achieved a significant milestone in its Phase 2 clinical study of cell-based hair regeneration, treating the trial’s 100th subject. With clinical sites expected to double in the coming months, the study will likely add dozens of additional subjects to its enrollment.

Atlanta, GA (PRWEB) February 28, 2010 -- Aderans Research Institute Inc. (ARI) recently achieved a significant milestone in its Phase 2 clinical study of cell-based hair regeneration, treating the trial’s 100th subject. With clinical sites expected to double in the coming months, the study will likely add dozens of additional subjects to its enrollment.

“The breadth of this phase of our trial is tremendous,” said Kurt Stenn, MD, Vice President and Chief Scientific Officer. “We have significantly more participants than our Phase 1 study. The improved quantity of our study group allows us to assess our cell-products and accelerate our efforts to truly understand the impact of cell regeneration on pattern hair loss.”

Phase 2 of the study has thus far been conducted in eight cities: Atlanta, Boston, Chicago, New York, Paramus, Raleigh, Houston, and Washington DC. The study will ultimately comprise at least 16 U.S. metropolitan areas, with numerous new cities expected to be added in the coming months.

The second phase of the trial is testing a variety of treatment regimens designed to realize a unique autologous cell engineering solution to hair regeneration. During the treatment, a small section of hair-bearing tissue is removed, cells are extracted and cultivated in a controlled laboratory setting, and then reintroduced to the scalp, where they are expected to elicit new hair growth.

“This is leading edge research in our industry,” said Vern Liebmann, Vice President, Operations. “We’ve been able to conduct this study largely due to the generous financial backing of Aderans Co. LTD of Japan, and we’re collectively very excited to see the results beginning later this year.”

Phase 1 of the clinical study was conducted exclusively in the UK. More than 30% of participants showed a viable response to ARI’s cellular regeneration techniques.

About Aderans Research

Aderans Research is a pioneer in the research and development of safe, effective cell engineered products for hair regeneration. With offices in Atlanta and Philadelphia, Aderans Research Institute is a subsidiary of Aderans Company, Ltd, the world’s largest wig manufacturer, and an affiliate of Bosley, a global leader in medical hair restoration.

More information on ARI’s study outcomes will be released as studies unfold. To see ARI’s latest clinical updates, please visit http://aderansresearch.com/ari_clinicalupdates.html

Additional information on ARI can be found at www.aderansresearch.com.

Learn more about Aderans Co., Ltd. At http://www.aderans.co.jp/e/company/

###

Read the full story at http://www.prweb.com/releases/hair/regeneration/prweb3661844.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Aderans Research BIO International Press Release
2. Aderans Research Launches Second Phase of Hair Loss Study
3. Veterans Affairs Researchers Induce a New Transmissible Prion Disease
4. Hypnosis can help control pain among women with metastatic breast cancer, UB Researcher finds
5. New Building at University of Michigan Health System Expands Eye Care, Unites Diabetes Researchers
6. Greenway Medical Technologies Donates Electronic Health Record, Clinical Research and Revenue Cycle Solutions to Northern Kentucky University
7. Multiple sclerosis, Italian researchers discover a possible onset mechanism for the disease
8. Coalition for Pulmonary Fibrosis and American Thoracic Society Continue Commitment to Pulmonary Fibrosis Research
9. HIV drug that protects a fetus should be avoided for one year after childbirth, researchers say
10. New Osteoarthritis Research Grant Program Initiated by AOSSM and Genzyme Biosurgery
11. $250,000 Grant Awarded for Groundbreaking Ligament and Tendon Repair Research
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Aderans Research Treats One-Hundredth Subject in Clinical Study
(Date:9/21/2017)... Falls Church, VA (PRWEB) , ... September 21, ... ... Use Policy , **An FDAnews Management Report**, http://www.fdanews.com/products/54818-promotional-communication      , In the ... every edge they can get while staying in compliance with FDA rules. , ...
(Date:9/21/2017)... WA (PRWEB) , ... September 21, 2017 , ... ... technology using Microscan’s LVS 7510 at the Global GS1 Healthcare Conference 2017 in ... of the life-sciences industry for ensuring label quality and improving patient safety. ...
(Date:9/21/2017)... ... September 21, 2017 , ... FlipBelt, the fitness brand that ... detail to the athletic wear market with the launch of their FlipBelt Crops. , ... their essentials securely at their fingertips while at the gym, on the trail, or ...
(Date:9/20/2017)... ... September 20, 2017 , ... FirstAlign ( http://www.firstalign.com ), combines ... Artificial Intelligence (AI) thinking, announced today the launch of its revamped web presence. ... information that offers a more comprehensive understanding of the organization’s business and machine ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... and commercialization, has just released a new white paper discussing the benefits ... than ever about medical device, pharmaceutical, and combination product organizations making sure ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)...   BioLife Solutions , Inc. (NASDAQ: BLFS ... grade cell and tissue hypothermic storage and ... , President and CEO, will be presenting at two investment ... Renshaw 19 th Annual Global Investment Conference on Tuesday, ... time). The conference is being held at the New York ...
(Date:9/6/2017)... , Sept. 6, 2017   PDI , a ... it will host an educational session focused on the ... infection (CLABSI) prevention at the 2017 Annual Scientific Meeting ... will take place at the Phoenix ... from Sept. 16-19, will also feature PDI,s ...
(Date:9/5/2017)... -- Sapheneia and Scannerside received FDA 510(k) clearance to ... third-party Vendor neutral CT product that makes it affordable ... current MITA standards. ... specifically designed to provide CT operators, prior to a ... a predefined threshold. Scannerside Dose Check is intended to ...
Breaking Medicine Technology: